Aligos Therapeutics (ALGS) Accumulated Expenses (2021 - 2025)
Historic Accumulated Expenses for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $13.6 million.
- Aligos Therapeutics' Accumulated Expenses fell 392.63% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 392.63%. This contributed to the annual value of $15.6 million for FY2024, which is 762.97% down from last year.
- As of Q3 2025, Aligos Therapeutics' Accumulated Expenses stood at $13.6 million, which was down 392.63% from $12.2 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Accumulated Expenses registered a high of $25.4 million during Q4 2021, and its lowest value of $11.0 million during Q1 2025.
- Its 5-year average for Accumulated Expenses is $15.3 million, with a median of $13.8 million in 2023.
- The largest annual percentage gain for Aligos Therapeutics' Accumulated Expenses in the last 5 years was 5663.11% (2022), contrasted with its biggest fall of 3990.33% (2022).
- Aligos Therapeutics' Accumulated Expenses (Quarter) stood at $25.4 million in 2021, then plummeted by 36.84% to $16.0 million in 2022, then rose by 5.01% to $16.8 million in 2023, then decreased by 7.63% to $15.6 million in 2024, then decreased by 12.55% to $13.6 million in 2025.
- Its Accumulated Expenses stands at $13.6 million for Q3 2025, versus $12.2 million for Q2 2025 and $11.0 million for Q1 2025.